ATTO (Attovia Therapeutics) Asset Turnover: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATTO Attovia Therapeutics Inc ATTO
8 GF Score
Price $20.38
View Full Analysis

What is Attovia Therapeutics Asset Turnover?

Attovia Therapeutics ATTO -6.94% 8 Asset Turnover is 0.00 as of Mar. 2026. GuruFocus rates ATTO with a GF Score™ of 8/100.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Attovia Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Attovia Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $155.99 Mil. Therefore, Attovia Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Attovia Therapeutics's annualized ROE % for the quarter that ended in Mar. 2026 was 64.07%. It is also linked to ROA % through Du Pont Formula. Attovia Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -47.84%.


Attovia Therapeutics  (NAS:ATTO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Attovia Therapeutics's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-74.624/-116.4755
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-74.624 / 0)*(0 / 155.9895)*(155.9895/ -116.4755)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-1.3392
=ROA %*Equity Multiplier
=-47.84 %*-1.3392
=64.07 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Attovia Therapeutics's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-74.624/155.9895
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-74.624 / 0)*(0 / 155.9895)
=Net Margin %*Asset Turnover
= %*0
=-47.84 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Attovia Therapeutics Asset Turnover Related Terms


Attovia Therapeutics Asset Turnover Historical Data

* Premium members only.

The historical data trend for Attovia Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Attovia Therapeutics Asset Turnover Chart

Attovia Therapeutics Annual Data
Trend Dec24 Dec25
Asset Turnover
0.00 0.01

Attovia Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Asset Turnover 0.00 0.00 0.00 0.00

ATTO vs : Asset Turnover Comparison

For the Biotechnology subindustry, Attovia Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Attovia Therapeutics Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Attovia Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Attovia Therapeutics's Asset Turnover falls into.


ATTO
8GF Score
Attovia Therapeutics Inc ATTO
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Attovia Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Attovia Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=1.35/( (76.716+165.893)/ 2 )
=1.35/121.3045
=0.01

Attovia Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (165.893+146.086)/ 2 )
=0/155.9895
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
Attovia Therapeutics (ATTO) has a Asset Turnover of 0.00 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Attovia Therapeutics and its competitors.
Is Attovia Therapeutics' Asset Turnover too high?
Attovia Therapeutics' current Asset Turnover is 0.00. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' Asset Turnover compare to ?
Attovia Therapeutics' Asset Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Attovia Therapeutics and its competitors. Attovia Therapeutics's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current Asset Turnover of 0.00. The current Asset Turnover is 0.00. Attovia Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current Asset Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Attovia Therapeutics Business Description

Comparable Companies
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score

Get the complete analysis for ATTO

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.38
Price